iStent inject models and other pipeline products. If any of these suppliers fail to provide sufficient quantities of components or drugs in a timely manner or on acceptable terms, Glaukos would ...

Analysts have set 12-month price targets for Glaukos, revealing an average target of $170.86, a high estimate of $200.00, and ...

Glaukos Co. (NYSE:GKOS – Get Free Report ... It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate ...

Glaukos has a beta of 0.99 ... It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle ...

ALISO VIEJO, Calif., April 16, 2025--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of ...

Conference Call and Webcast Scheduled for 1:30 p.m. PT ALISO VIEJO, Calif., April 09, 2025--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology ...

iStent inject models and other pipeline products. If any of these suppliers fail to provide sufficient quantities of components or drugs in a timely manner or on acceptable terms, Glaukos would ...

Glaukos Corp is an ophthalmic pharmaceutical ... device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite. Market Capitalization Analysis: The company ...

Strong Product Demand: Glaukos' rising share price is largely driven by the success of its flagship product, iStent. The company delivered robust performance during 2024 and maintains a favorable ...